Navigation Links
Stemgent Announces Sponsorship of Harvard Stem Cell Institute Seminar Series;
Date:9/1/2009

BOSTON, Sept. 1 /PRNewswire/ -- Stemgent, Inc. announced today that it has pledged a financial gift to the Harvard Stem Cell Institute (HSCI) Seminar Series Fund in support of the HSCI 2009 - 2010 Seminar Series. Terms of the gift were not disclosed.

The HSCI Seminar Series is an educational program for the stem cell science community in which pioneers in the national and international realm of stem cell research, including many from the Harvard-affiliated senior faculty, present contemporary stem cell topics. Speakers are nominated by HSCI faculty and selected by the HSCI. The series are typically well attended and are recognized for fostering collaboration within the HSCI community as well as involving participation from the global stem cell scientific population.

"We're pleased to be able to fund this prestigious seminar series and we're very proud of our ongoing relationship with HSCI through our Scientific Advisory Board which includes Harvard's Lee Rubin and Doug Melton, " said Ian Ratcliffe, Stemgent's president and chief executive officer. " HSCI has a top-notch research team, displays a global scientific acumen and it's always a great pleasure to work with them."

Brock Reeve, Executive Director of HSCI, commented, "The HSCI Seminar Series is focused on enabling scientific interchange among experts in the stem cell field from around the world. HSCI is very pleased that Stemgent, a company focused on addressing the needs of stem cell scientists, has agreed to partner with us by supporting this series."

About the Harvard Stem Cell Institute

Founded in 2004, the Harvard Stem Cell Institute (HSCI) is a scientific collaborative that brings together researchers from across Harvard's many affiliated hospitals, institutes, and schools to accelerate stem cell science from the laboratory bench to the patient bedside. With 72 Principal Faculty and 146 Affiliate Faculty, the HSCI represents the world's largest concentration of stem cell researchers. Using philanthropic dollars, HSCI provides three programs of support for its community: a Research Grant program; an Ethics and Policy Program; and, an Education Program. For more information, please visit http://www.hsci.harvard.edu.

About Stemgent

Stemgent advances stem cell science by providing proprietary reagents and tools developed by some of the world's leading stem cell scientists. Stemgent's product offering has been specifically optimized for and screened against stem cells, and includes small molecules for pluripotency, self-renewal, and differentiation, viral-delivered transcription factors, matrices, cell lines, cytokines, antibodies, transfection reagents, and more. This unique product mix is designed to serve researchers who study stem cell biology and regenerative medicine, and those who use cells derived from stem cells as tools to advance their understanding of major diseases. With dual headquarters in Boston, MA, and San Diego, CA, Stemgent is well positioned to serve these major research markets. For more information, please visit http://www.stemgent.com.


'/>"/>
SOURCE Stemgent, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston Scientific Announces Schedule for European Society of Cardiology Congress
2. ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis
3. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
4. ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once-Daily Xibrom(TM) 0.09%
5. IDEV(R) Technologies Announces First Patient Enrolled in Multi-Center Clinical Trial of SUPERA(R) PERipheral Stent
6. Phytomedics Inc. Announces Publication of the Phase 2b Clinical Trial Results of an Extract of the Chinese Herbal Remedy Tripterygium wilfordii Hook F in Rheumatoid Arthritis
7. Bionovo Announces Second Quarter 2009 Highlights and Financial Results
8. Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
9. NewCardio Announces Master Services Agreement With Dedicated Phase I
10. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
11. Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Calif. , June 24, 2016  American Respiratory Labs (ARL), ... is now able to perform sophisticated lung assessments in patients, homes, ... , Inc. Patients are no longer limited to ... EasyOne PRO ® , ARL patients like Jeanne R. of ... in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm ... sciences executive with extensive sequencing and genomics experience, as Vice President of North American ... Hill will be responsible for leading the sales team in the commercialization of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... To succeed under value-based payments, ... are unsure how to move forward, given the need to sustain current operations. ... tailored to an organization’s specific needs. , PYA Principal Martie Ross states, “Healthcare ...
(Date:6/23/2016)... ... June 23, 2016 , ... Terumo BCT, ... organization responsible for clinical transfusion research programs and for the blood supply in ... Evaluation and Predictive Analytical Rating Score (PREPAReS) study. , Currently in its ...
Breaking Medicine News(10 mins):